MAPK9 and leukemia: Due to the important key roles of JNK-2 in cancer progression through the control of proliferation, differentiation, survival, and migration, JNK-2 becomes an appealing oncogenic target for cancer therapy due to its high expression in a variety of cancers, including colorectal adenocarcinoma, cervical cancer, pancreatic cancer, hepatocellular carcinoma, and leukemia [16,17,18,19,20,21,22].